Adaptive Biotechnologies Corporation (ADPT)

NMS – Real vaqt narxi. Valyuta: USD

13.63

+0.09 (0.66%)

Yopilishda: May 12, 2026, 4:00 PM EDT

06.05.2026

Adaptive Biotechnologies Corporation (ADPT) Q1 2026 Earnings Call Transcript

05.05.2026

Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

05.05.2026

Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.2 per share a year ago.

05.05.2026

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2026. “We delivered strong first quarter results based on accelerating adoption of MRD across both clinical testing and drug development.

20.04.2026

Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means

44,166 Common shares were sold directly for a transaction value of approximately ~$758,000, based on a weighted average sale price of $13.26 per share across April 9, 10, and 13, 2026. The disposition represented 11.95% of Julie Rubinstein's direct holdings at the time of sale, leaving her with 421,174 directly held shares following the reported transactions.

18.04.2026

Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares?

57,180 shares were sold for a total transaction value of approximately ~$826,000 across multiple days ending April 16, 2026. This sale represented 12.29% of Rubinstein's direct holdings at the time, reducing her directly held Common Stock to 408,160 shares.

15.04.2026

Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026

SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2026 after market close on Tuesday, May 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Videolar

No Data

There is no data to display

Press-relizlar

05.05.2026

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

05.02.2026

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2025.

12.01.2026

Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

SEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025. Total revenue for the fourth quarter and full year 2025 was approximately $72 million and $277 million, representing an increase of 51% and 55%, respectively, over the corresponding periods in 2024.

15.12.2025

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive's proprietary TCR-antigen datasets for research and development in multiple immunology applications SEATTLE, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced two non-exclusive agreements with Pfizer Inc. (NYSE: PFE) to leverage Adaptive's proprietary T-cell receptor (TCR) discovery capabilities and large-scale immune receptor antigen mapping data. Discovering disease-causing TCRs in rheumatoid arthritis Adaptive has identified autoreactive or ‘offender' TCRs that could potentially cause disease in patients with autoimmune indications.

Adaptive Biotechnologies Corporation (ADPT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Adaptive Biotechnologies Corporation (ADPT)

Adaptive Biotechnologies Corporation (ADPT) Q1 2026 Earnings Call Transcript

Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means

Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares?

Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026

Videolar

No Data

Press-relizlar

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

Adaptive Biotechnologies Corporation (ADPT) Q1 2026 Earnings Call Transcript

Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means

Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares?

Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026

Videolar

No Data

Press-relizlar

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

Search stocks

Adaptive Biotechnologies Corporation (ADPT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Adaptive Biotechnologies Corporation (ADPT)

Adaptive Biotechnologies Corporation (ADPT) Q1 2026 Earnings Call Transcript

Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means

Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares?

Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026

Videolar

No Data

Press-relizlar

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

Adaptive Biotechnologies Corporation (ADPT) Q1 2026 Earnings Call Transcript

Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means

Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares?

Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026

Videolar

No Data

Press-relizlar

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer